CA
JAZZ icon

Crewe Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Crewe Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20
Closed -$2.46K – 975
2023
Q4 		$2.46K Buy
+20
New +$2.5K ﹤0.01% 287
2023
Q3 		– Sell
-20
Closed -$2.48K – 749
2023
Q2 		$2.48K Sell
20
-44
-69% -$5.92K ﹤0.01% 518
2023
Q1 		$9.37K Hold
64
– – ﹤0.01% 561
2022
Q4 		$10.2K Hold
64
– – ﹤0.01% 548
2022
Q3 		$9K Hold
64
– – ﹤0.01% 697
2022
Q2 		$10K Buy
+64
New +$9.85K ﹤0.01% 594
2022
Q1 		– Sell
-60
Closed -$8K – 485
2021
Q4 		$8K Buy
+60
New +$7.88K ﹤0.01% 326

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Crewe Advisors's JAZZ Position: Q1 2024 in Review

Crewe Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 20 shares — an estimated $2.46K sold.

Crewe Advisors first reported a position in JAZZ in Q4 2021 and held it in 7 quarters. The position peaked at $10.2K in Q4 2022. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

  • Crewe Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Crewe Advisors sold 20 Jazz Pharmaceuticals shares in Q1 2024, an estimated $2.46K.
  • Crewe Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and held it in 7 quarters.
  • Crewe Advisors's Jazz Pharmaceuticals position peaked at $10.2K in Q4 2022.
  • 481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Crewe Advisors's 13F filing for Q1 2024, filed 14 May 2024.